← Leaderboards
P. Worth Longest
Virginia Commonwealth University
$9,813,926
Attributed
$14,789,365
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,744,103 · 8
FDA$1,045,262 · 2
By mechanism
R01$11,843,907 · 4
R21$1,180,823 · 3
U01$1,045,262 · 2
R56$719,373 · 1
Top collaborators
- Michael Hindle19 shared
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Michael Hindle$5,431,031
Others in their field
Top investigators on “Aerosols”
- Kimberly A Prather · University Of California-Riverside$46,542,272
- Thomas Gary Ksiazek · University Of Texas Med Br Galveston$32,195,929
- Jeffery Dill · Battelle Centers/Pub Hlth Res & Evaluatn$30,023,104
- Barton F Haynes · Duke University$27,999,998
- Charles L Bailey · George Mason University$27,475,000
- Deepak Kaushal · University Of Chicago$26,419,545
Research focus
AerosolsIn VitroParticleDevicesLungDoseGrowthLiquid SubstanceExcipientsDepositionAdultNebulizerNosePharmaceutical PreparationsWettabilityBaseExhalationRespiratoryFormulationCannulasCystic FibrosisParticle SizePowder Dose FormDrug Delivery Systems
Grant awards (34)
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support$736,563
R01 · FY2025 · HL · contact PI
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support$733,241
R01 · FY2024 · HL · contact PI
Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Metered Dose Inhalers$99,146
U01 · FY2024 · FD · contact PI
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support$73,068
R01 · FY2024 · HL · contact PI
Preclinical development of a synthetic lung surfactant dry powder aerosol for hypoxemia or acute respiratory distress syndrome patients receiving different modes of ventilation support$758,312
R01 · FY2023 · HL · contact PI
Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Metered Dose Inhalers$199,639
U01 · FY2023 · FD · contact PI
Preclinical development of a synthetic lung surfactant dry powder aerosol for acute respiratory distress syndrome patients receiving different modes of ventilation support$719,373
R56 · FY2022 · HL · contact PI
Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Metered Dose Inhalers$199,329
U01 · FY2022 · FD · contact PI
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$734,852
R01 · FY2021 · HL · contact PI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$475,680
R01 · FY2021 · HD · contact PI
Computational Fluid Dynamics (CFD) Models to Aid the Development of Generic Metered Dose Inhalers$199,850
U01 · FY2021 · FD · contact PI
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$723,687
R01 · FY2020 · HL · contact PI
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$612,895
R01 · FY2020 · HL · contact PI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$517,950
R01 · FY2020 · HD · contact PI
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$688,568
R01 · FY2019 · HL · contact PI
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$597,412
R01 · FY2019 · HL · contact PI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$527,772
R01 · FY2019 · HD · contact PI
High Efficiency Delivery of Surfactant Aerosols to Infants without Intubation$692,453
R01 · FY2018 · HL · contact PI
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$577,528
R01 · FY2018 · HL · contact PI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$519,041
R01 · FY2018 · HD · contact PI
High Efficiency Aerosol Delivery using the Excipient Enhanced Growth Concept: A Human Proof of Concept Study$585,153
R01 · FY2017 · HL · contact PI
High Efficiency Inhalation Delivery of Tobramycin for Children with Cystic Fibrosis$489,791
R01 · FY2017 · HD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$428,345
R01 · FY2015 · HL · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$432,679
R01 · FY2014 · HL · contact PI
Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug$47,583
U01 · FY2014 · FD · contact PI
Nanoaerosols from Wick Electrospray for Improved Drug Delivery to Infants$206,226
R21 · FY2013 · HD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$466,534
R01 · FY2012 · HL · contact PI
Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug$299,715
U01 · FY2012 · FD · contact PI
Nanoaerosols from Wick Electrospray for Improved Drug Delivery to Infants$169,805
R21 · FY2012 · HD · contact PI
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation$472,383
R01 · FY2011 · HL · contact PI
Excipient enhanced aerosol particle formulations and inhaler development for impr$224,250
R21 · FY2011 · HL
Excipient enhanced aerosol particle formulations and inhaler development for impr$183,905
R21 · FY2010 · HL
Improved Lung Delivery of Medical Aerosols through Enhanced Condensation Growth$182,421
R21 · FY2010 · HL · contact PI
Improved Lung Delivery of Medical Aerosols through Enhanced Condensation Growth$214,216
R21 · FY2009 · HL · contact PI